ADVIL ALLERGY SINUS pharmaceutical API fine chemical vendors

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Start Trial	2023-05-9C03841	⤷ Start Trial
RR Scientific	⤷ Start Trial	R6213494	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: February 19, 2026

Advil Allergy & Sinus is an over-the-counter medication combining the analgesic and anti-inflammatory properties of ibuprofen with the decongestant effects of pseudoephedrine hydrochloride. This analysis identifies key bulk API suppliers and relevant patent landscapes impacting its manufacturing and market.

What are the Primary Active Pharmaceutical Ingredients in Advil Allergy & Sinus?

The two principal active pharmaceutical ingredients (APIs) in Advil Allergy & Sinus are:

Ibuprofen: A nonsteroidal anti-inflammatory drug (NSAID) used to reduce fever and pain.
Pseudoephedrine Hydrochloride: A sympathomimetic amine that acts as a nasal decongestant.

Who are the Major Manufacturers of Ibuprofen API?

The global ibuprofen API market is substantial and characterized by several large-scale manufacturers, primarily located in Asia. Key players include:

BASF SE: A German chemical company with significant pharmaceutical API production, including ibuprofen.
SICHUAN HEPTAIN PHARMACEUTICAL CO., LTD.: A Chinese manufacturer specializing in pharmaceutical raw materials and intermediates.
SIROJ PHARMACEUTICALS PVT. LTD.: An Indian pharmaceutical company producing a range of APIs.
JIANGSU JIUGUO PHARMACEUTICAL CO., LTD.: A Chinese producer of pharmaceutical chemicals.
HUANSHAN ZHENXING PHARMACEUTICAL CO., LTD.: Another Chinese manufacturer involved in API production.
ICONE PHARMA LIMITED: An Indian API manufacturer.
ZHENGZHOU HUIJIU PHARMACEUTICAL CO., LTD.: A Chinese pharmaceutical enterprise.
LUPIN LIMITED: A multinational pharmaceutical company based in India, with API manufacturing capabilities.
AUROBINDO PHARMA LIMITED: An Indian multinational pharmaceutical company known for its generic drug manufacturing and API production.
NOVARTIS AG: While primarily known for finished dosage forms, Novartis also operates API production facilities.

The primary manufacturing hubs for ibuprofen API are China and India, driven by cost efficiencies and established chemical manufacturing infrastructure. Production volumes can reach tens of thousands of metric tons annually for the major players.

What are the Key Suppliers of Pseudoephedrine Hydrochloride API?

Pseudoephedrine hydrochloride production is more tightly regulated due to its potential diversion for illicit methamphetamine synthesis. Major suppliers are fewer and subject to stringent controls.

Purdue Pharma L.P.: Historically a significant producer, though current operations are subject to change.
Amneal Pharmaceuticals LLC: A U.S.-based generics manufacturer with API capabilities.
TEVA PHARMACEUTICAL INDUSTRIES LTD.: A global pharmaceutical leader with extensive API manufacturing across various therapeutic areas.
ABBVIE INC.: A biopharmaceutical company that may produce or source pseudoephedrine hydrochloride for its own product lines.
BAYER AG: A German multinational pharmaceutical and life sciences company with a broad portfolio including API production.

Due to regulatory scrutiny, specific production volumes and market share data for pseudoephedrine hydrochloride API are less publicly disclosed than for ibuprofen. Countries like the United States and Switzerland house some of the key manufacturing entities or supply chain nodes.

What is the Patent Landscape for Ibuprofen Synthesis and Formulations?

The fundamental patents for ibuprofen's discovery and initial synthesis, including the Boots process, expired decades ago. However, ongoing innovation focuses on:

Improved Synthesis Routes: Patents may cover more efficient, cost-effective, or environmentally friendly methods of producing ibuprofen. These often involve novel catalysts, reaction conditions, or purification techniques.
- For example, patents may claim a new process for producing ibuprofen with a yield greater than X% or a purity level exceeding Y%.
- Specific examples of patented synthetic steps might include novel cyclization reactions or esterification methods.
Novel Formulations: Patents frequently protect specific pharmaceutical compositions designed to enhance drug delivery, stability, or patient compliance. This can include:
- Controlled-release formulations: Patents in this area aim to prolong the duration of action or reduce dosing frequency. These may involve specific polymer matrices, encapsulation techniques, or osmotic pump systems.
- Combination therapies: While Advil Allergy & Sinus is a combination product, patents may cover novel synergistic combinations of ibuprofen with other active ingredients or specific excipient profiles that improve the efficacy or reduce side effects of the combined drug.
- Solubilized forms: Patents might claim methods for creating more soluble forms of ibuprofen, potentially leading to faster absorption and onset of action.
Chiral Separation: Ibuprofen is a racemic mixture of R-(-)-ibuprofen and S-(+)-ibuprofen. While the racemic mixture is commonly used, patents might exist for processes that efficiently produce or isolate the more pharmacologically active S-(+)-enantiomer, although this is less common for the OTC market due to cost and complexity.
Polymorphs and Crystalline Forms: Patents can protect specific crystalline structures (polymorphs) of ibuprofen API that offer advantages in terms of stability, dissolution rate, or manufacturing processability.

The expiration of early composition of matter patents has shifted the focus to process patents and formulation patents, which provide continued intellectual property protection for manufacturers and formulators.

What is the Patent Landscape for Pseudoephedrine Hydrochloride Synthesis and Formulations?

Similar to ibuprofen, the foundational patents for pseudoephedrine are long expired. However, intellectual property in this area often relates to:

Manufacturing Processes: Patents may cover refined chemical synthesis pathways that offer higher purity, reduced byproducts, or increased efficiency in producing pseudoephedrine hydrochloride.
- These processes often focus on specific reaction steps, catalysts, or solvent systems.
Controlled-Release Formulations: Given the regulatory concerns and the desire for extended relief, many patents surround controlled-release mechanisms for pseudoephedrine. These aim to:
- Mitigate diversion risk by embedding the API within matrices that are difficult to extract.
- Provide a consistent level of decongestant effect over a specified period (e.g., 12 or 24 hours).
- Patented technologies might include osmotic systems, hydrophilic matrix systems, or specialized coating technologies.
Combination Products: Patents may protect the specific combination of pseudoephedrine hydrochloride with other APIs, particularly if there is a demonstrated synergistic effect or improved therapeutic profile compared to administering the drugs separately.
Stabilization Techniques: Patents might address methods to improve the long-term stability of pseudoephedrine hydrochloride in pharmaceutical formulations, preventing degradation and ensuring product shelf-life.

The regulatory environment surrounding pseudoephedrine significantly influences the patent landscape, with an emphasis on formulations that deter misuse and ensure controlled release.

How Do Regulations Impact API Sourcing and Manufacturing?

The sourcing and manufacturing of both ibuprofen and pseudoephedrine hydrochloride are subject to extensive regulatory oversight.

Good Manufacturing Practices (GMP): All API manufacturers must adhere to stringent GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This ensures the quality, purity, and consistency of the API.
- GMP compliance involves rigorous documentation, quality control, process validation, and facility standards.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API. Drug product manufacturers reference these DMFs in their marketing authorization applications.
Controlled Substance Regulations (for Pseudoephedrine): Pseudoephedrine hydrochloride is classified as a List I chemical by the U.S. Drug Enforcement Administration (DEA) and faces similar controls internationally. This means:
- Manufacturers, distributors, and purchasers of pseudoephedrine hydrochloride are subject to registration, record-keeping, and reporting requirements.
- Sales are often limited in quantity, and purchasers may need to show identification.
- Import and export of pseudoephedrine hydrochloride are strictly controlled.
REACH and Other Chemical Regulations: European Union regulations like REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) impact the sourcing and use of chemical substances, including APIs, within the EU market. Similar chemical control laws exist in other major markets.
Quality Agreements: Pharmaceutical companies that purchase APIs enter into detailed Quality Agreements with their API suppliers. These agreements define the responsibilities of each party concerning quality control, specifications, change management, and audits, ensuring the consistent quality of the API used in finished drug products.

These regulations add significant costs and complexity to the supply chain but are essential for ensuring patient safety and preventing the diversion of controlled substances.

What are the Key Considerations for Sourcing Advil Allergy & Sinus APIs?

Companies seeking to source bulk APIs for Advil Allergy & Sinus formulations must consider several critical factors:

API Purity and Quality: Sourcing from manufacturers with a proven track record of consistently meeting pharmacopeial standards (e.g., USP, EP, JP) is paramount.
- Verification of GMP compliance through audits and review of regulatory filings is essential.
Supply Chain Reliability and Security: Given the global nature of API manufacturing, ensuring a robust and reliable supply chain is critical. This includes:
- Assessing the financial stability and operational capacity of suppliers.
- Diversifying suppliers to mitigate risks associated with single-source dependencies, particularly for pseudoephedrine hydrochloride.
- Understanding lead times and inventory management strategies.
Regulatory Compliance: The chosen API suppliers must demonstrate full compliance with all applicable national and international regulations, including GMP, controlled substance regulations, and chemical control laws.
- Reviewing supplier DMFs and ensuring they are accepted by target regulatory authorities.
Cost-Effectiveness: While quality and compliance are non-negotiable, competitive pricing is a key driver in the generics and OTC markets.
- Evaluating the total cost of ownership, including shipping, quality control, and regulatory compliance support.
Technical Support and Collaboration: Access to technical expertise from the API supplier for formulation development, troubleshooting, and regulatory inquiries can be invaluable.
Intellectual Property Landscape: Understanding existing patents related to synthesis processes and formulations is crucial to avoid infringement and to identify opportunities for innovation or generic market entry. This includes assessing the freedom to operate (FTO) for specific sourcing and manufacturing strategies.

Key Takeaways

The primary APIs for Advil Allergy & Sinus are ibuprofen and pseudoephedrine hydrochloride.
Ibuprofen API manufacturing is dominated by large-scale producers in China and India, with companies like BASF, Sichuan Heptain, and Jiangsu Jiuguo being key players.
Pseudoephedrine hydrochloride API sourcing is more restricted due to regulatory controls, with manufacturers such as Teva Pharmaceuticals and Amneal Pharmaceuticals being significant entities.
The patent landscape for these APIs is primarily characterized by process improvements and novel formulation technologies, rather than composition of matter patents.
Stringent regulations, including GMP and controlled substance laws, heavily influence API sourcing and manufacturing, demanding robust compliance from suppliers.
Strategic API sourcing requires a comprehensive evaluation of purity, supply chain reliability, regulatory adherence, cost, and technical support.

Frequently Asked Questions

1. What are the main quality control parameters for ibuprofen and pseudoephedrine hydrochloride APIs?

Key quality control parameters include purity (often measured by HPLC), identification (e.g., IR spectroscopy), assay (potency), residual solvents, heavy metals, related substances (impurities), and physical characteristics such as particle size distribution and moisture content. For pseudoephedrine hydrochloride, specific testing for enantiomeric purity and absence of regulated precursors is also critical.

2. How does the DEA regulation of pseudoephedrine hydrochloride affect API sourcing for U.S. manufacturers?

U.S. manufacturers sourcing pseudoephedrine hydrochloride must work with DEA-registered manufacturers and distributors. They are subject to record-keeping requirements for all transactions, including quantities purchased, dates, and customer information. Limits on the retail sale of products containing pseudoephedrine are also a significant market consideration that influences manufacturing demand.

3. Are there any significant patent cliffs expected for current Advil Allergy & Sinus formulations or their API production methods in the near future?

Given that the core patents for ibuprofen and pseudoephedrine themselves have long expired, the focus for patent cliffs would be on specific, newer process patents or formulation patents. Companies would need to conduct detailed patent landscape analyses for specific manufacturing processes or advanced controlled-release technologies to identify potential patent expirations that could open avenues for generic competition.

4. What is the typical lead time for sourcing bulk quantities of ibuprofen and pseudoephedrine hydrochloride APIs?

Lead times can vary significantly depending on the supplier, current market demand, and the specific quantity ordered. For ibuprofen, which is produced in high volumes, lead times might range from 4 to 12 weeks. For pseudoephedrine hydrochloride, due to tighter supply chains and regulatory requirements, lead times can be longer, potentially 8 to 20 weeks, and are heavily influenced by supplier inventory and production schedules.

5. How do international quality standards (e.g., ICH guidelines) influence API supplier selection?

International Council for Harmonisation (ICH) guidelines, such as ICH Q7 for GMP for APIs, are foundational for API quality and regulatory acceptance worldwide. Suppliers adhering to ICH guidelines demonstrate a commitment to robust quality systems that are recognized by major regulatory agencies like the FDA and EMA, simplifying the regulatory approval process for finished drug products and ensuring a higher level of product safety and consistency.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [Specific FDA resource URL, if available, or general reference to FDA DMF guidance] [2] Drug Enforcement Administration. (n.d.). List I Chemicals. Retrieved from [Specific DEA resource URL, if available, or general reference to DEA controlled substances list] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Q7 GMP Guide. Retrieved from [Specific ICH website resource URL] [4] European Chemicals Agency. (n.d.). REACH Regulation. Retrieved from [Specific ECHA website resource URL]

Bulk Pharmaceutical API Sources for ADVIL ALLERGY SINUS